Recursion Pharmaceuticals, Inc. (RXRX) stock
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
Earnings
Recursion Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Recursion Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 15, 2026before the open | – | – | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026before the open | $7.70M | -59.9% | -$0.25 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026before the open | $6.50M | -56.7% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026before the open | $35.50M | +688.9% | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025before the open | $5.20M | -80.1% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $19.20M | – | -$0.41 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 5, 2025before the open | $15.00M | +8.7% | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 28, 2025before the open | $4.50M | -58.7% | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024after the close | $26.10M | +148.6% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | $13.80M | +14.0% | -$0.39 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024after the close | $10.90M | -20.4% | -$0.42 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023before the open | $10.50M | -20.5% | -$0.43 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | $11.00M | +42.9% | -$0.38 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023before the open | $12.10M | +128.3% | -$0.34 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 27, 2023after the close | $13.70M | +448.0% | -$0.31 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | $13.20M | +428.0% | -$0.35 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022after the close | $7.70M | – | -$0.38 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022after the close | $5.30M | – | -$0.33 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 23, 2022before the open | $2.50M | – | -$0.38 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021before the open | $2.50M | – | -$0.28 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 13, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 12, 2021before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Recursion Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| cash operating expensenon-GAAP | FY2026 | $375.00M | – | Lowered | Aug 5, 2026 |
| operating cash expense, excluding partnership inflows and transaction costsnon-GAAP | FY2026 | $390.00M | – | New | Feb 25, 2026 |
| operational cash burn | FY2026 | $390.00M | – | New | May 6, 2026 |
Guidance history
Every forecast Recursion Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 5, 2026 | cash operating expense | FY2026 | $375.00M | Lowered |
| May 6, 2026 | operational cash burn | FY2026 | $390.00M | New |
| Feb 25, 2026 | operating cash expense, excluding partnership inflows and transaction costs | FY2026 | $390.00M | New |
| May 5, 2025 | cash burn | FY2025 | $450.00M | New |
| Feb 28, 2025 | synergies | FY2025 | $100.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Recursion Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- Results
See a number that looks wrong?